McKechnie Duncan sold $800K of VRTX

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b results for inaxaplin in kidney disease, with a 45 mg once-daily regimen showing a safe profile. The company completed enrollment in the Phase 2/3 AMPLITUDE trial, aiming to diversify its pipeline beyond cystic fibrosis. Analysts forecast revenue of $17.2B and earnings of $6.5B by 2029, with potential upside if kidney and gene editing efforts succeed.

Vertex Pharmaceuticals (VRTX) reported Phase 2b AMPLIFIED results for inaxaplin in APOL1-mediated kidney disease, completing pivotal trial enrollment. Shares traded at $516.34, with mixed short-term performance. Analysts suggest undervaluation, with fair value estimates ranging from $558.68 to $681.83, citing pipeline diversification and long-term growth potential.

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b trial results for inaxaplin in treating APOL1-mediated kidney disease. The drug showed significant proteinuria reductions in two patient groups, with a favorable safety profile. Vertex expects interim Phase 2/3 trial results in early 2027, which could support U.S. approval. William Blair reiterated an Outperform rating, citing potential growth. VRTX shares rose 2.04% to $521.14.

Vertex Pharmaceuticals (VRTX) shares rose 3% after reporting positive trial results for inaxaplin in APOL1-mediated kidney disease (AMKD). The drug reduced protein leakage in urine by 42.7% for albumin and 44.7% for total protein in patients with modest proteinuria. Rival Maze Therapeutics (MAZE) shares jumped 25% on the read-through. Truist called the data a validation of APOL1 inhibition, estimating a market of over 100,000 patients and potential blockbuster sales for Maze's MZE829.

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b results for Inaxaplin in additional patient groups with APOL1-mediated kidney disease, showing reductions in kidney damage markers. The company completed enrollment in its Phase 2/3 AMPLITUDE trial, with interim results expected in early 2027. Inaxaplin was generally safe and well-tolerated. VRTX stock is up 2.88% at $525.18.

H.C. Wainwright maintained a Buy rating and $641 price target for Vertex (VRTX), citing positive AMPLIFIED Cohort 1 data. The stock trades at $523.42, with a consensus Buy rating and high target of $672. Vertex's market cap is $132.3 billion, and it has delivered a 33% return over the past year. Other analysts also reiterated positive ratings and targets, reflecting confidence in Vertex's pipeline.